New ultrasound agent matches nuclear medicine
This article was originally published in Clinica
Preclinical studies show that Acusphere's new ultrasound contrast agent has the potential to simplify contrast echocardiography because it can be detected continuously after bolus administration. Trials of AI-700 in dogs show that gas-filled synthetic polymer microspheres detect areas of low blood flow in the heart muscle, in high agreement with nuclear medicine, the current gold standard for detecting heart prefusion defects, say cardiologists at Tufts-New England Medical Center in Boston.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.